These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34328370)

  • 21. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
    Sanchez IM; Sorenson E; Levin E; Liao W
    Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.
    Schafer JA; Kjesbo NK; Gleason PP
    J Manag Care Pharm; 2010; 16(6):402-16. PubMed ID: 20635831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study.
    Zagni E; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Zullo A; Fiocchi M; Colombo D
    BMC Health Serv Res; 2021 Sep; 21(1):924. PubMed ID: 34488749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Biologic therapies in the treatment of psoriasis].
    Farhi D; Dupin N
    Presse Med; 2009 May; 38(5):832-43. PubMed ID: 19282134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.
    Sorenson E; Koo J
    J Dermatolog Treat; 2015; 26(6):493-501. PubMed ID: 25886082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.
    Hu Y; Chen Z; Gong Y; Shi Y
    Clin Drug Investig; 2018 Mar; 38(3):191-199. PubMed ID: 29249053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
    Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting.
    Gulliver WP; Randell S; Gulliver S; Gregory V; Nagle S; Chambenoit O
    J Cutan Med Surg; 2018; 22(6):567-576. PubMed ID: 29952225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K; Burden AD; Eaton JN; Hawkins NS
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted therapies for pediatric psoriasis.
    Schwartz G; Paller AS
    Semin Cutan Med Surg; 2018 Sep; 37(3):167-172. PubMed ID: 30215634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
    Armstrong AW; Read C
    JAMA; 2020 May; 323(19):1945-1960. PubMed ID: 32427307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans.
    Feldman SR; Wu JJ; Rastogi S; Menges B; Lingohr-Smith M; Lin J
    J Med Econ; 2018 May; 21(5):537-541. PubMed ID: 29357713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
    Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
    J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.
    Croxtall JD
    Drugs; 2011 Sep; 71(13):1733-53. PubMed ID: 21902296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term data.
    Gil-Sierra MD; Ríos-Sánchez E; Briceño-Casado MDP
    Farm Hosp; 2020 Jul; 44(5):218-221. PubMed ID: 32853127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.
    Rungapiromnan W; Mason KJ; Lunt M; McElhone K; Burden AD; Rutter MK; Warren RB; Griffiths CEM; Ashcroft DM;
    J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):769-778. PubMed ID: 31633837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.